Neurocrine Biosciences Inc annual operating income for fiscal TTM was $789 million, an increase of 27.5% from $619 million in fiscal 2025. All figures are reported results from public filings — no estimates or projections.
| Operating Income (annual) | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 | 2011-12-31 | 2010-12-31 | 2009-12-31 | 2008-12-31 | 2007-12-31 | 2006-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income (EBIT) | $789M | $619M | $570M | $251M | $249M | $102M | $163M | $72M | $37M | ($131M) | ($147M) | ($94M) | ($64M) | ($50M) | $1M | $34M | ($14M) | ($54M) | ($87M) | ($212M) | ($113M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Operating Income (quarterly) | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
|---|---|---|---|---|---|---|---|---|---|
| Operating Income (EBIT) | $153M | $186M | $211M | $239M | $146M | $24M | $142M | $184M | $145M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
More NBIX metrics: Revenue · Gross Profit · Net Income · EPS · EBITDA · Free Cash Flow · Shares Outstanding
All NBIX financial statements → Interactive NBIX charts →
About TickerBase · Data methodology & sources · Privacy · Terms